

# Tata Consumer Products

Estimate change	↔
TP change	↔
Rating change	↔

**CMP: INR761      TP: INR880 (+16%)      Buy**

## Strong Standalone offsets weak International business

Bloomberg	TATACONS IN
Equity Shares (m)	922
M.Cap.(INRb)/(USD\$b)	701.7 / 8.5
52-Week Range (INR)	861 / 651
1, 6, 12 Rel. Per (%)	-5/-10/-4
12M Avg Val (INR M)	1595
Free float (%)	65.3

### Financials & valuations (INR b)

Y/E MARCH	2022	2023E	2024E
Sales	124.3	137.7	152.0
EBITDA	17.2	18.9	24.0
Adj. PAT	9.7	11.3	16.6
EBITDA Margin (%)	13.8	13.8	15.8
Cons. Adj. EPS (INR)	10.6	12.2	17.4
EPS Gr. (%)	11.8	15.4	42.4
BV/Sh. (INR)	164.3	176.0	189.6

### Ratios

Net D:E	-0.1	-0.1	-0.2
RoE (%)	6.6	7.2	9.6
RoCE (%)	9.0	10.1	12.5
Payout (%)	59.6	46.8	37.4

### Valuations

P/E (x)	72.0	62.4	43.8
EV/EBITDA (x)	39.8	36.2	28.1
Div. Yield (%)	0.8	0.8	0.9
FCF Yield (%)	1.8	0.5	2.3

### Shareholding pattern (%)

As On	Jun-22	Mar-22	Jun-21
Promoter	34.7	34.7	34.7
DII	14.0	13.7	14.0
FII	25.4	25.4	25.1
Others	25.9	26.2	26.3

Note: FII includes depository receipts

### Operating performance in line

- Tata Consumer Products (TATACONS)'s Standalone operating performance was strong led by EBIT margin expansion of ~190bp YoY (mainly due to gross margin expansion of ~210bp YoY) in 2QFY23. The strong Standalone performance offset the contraction in International business margins (EBIT margin contracted ~690bp) led by input cost inflation, currency weakness and lag in pricing. This resulted in muted Consolidated business performance, with EBIT margin contracting ~60bp YoY to 10.7% in 2QFY23.
- The company is on a portfolio expansion spree in its F&B segment, with product launches in new and innovative categories such as recent launch of Tata Sampann Hing and its foray into Protein-based product categories with the launch of a plant-based protein supplement Tata GoFit.
- Factoring in an in-line performance in 2QFY23, we maintain our FY23 and FY24 earnings estimates. **We maintain our BUY rating on the stock with an SoTP-based TP of INR880.**

### Realization growth drives overall sales

- TATACONS posted a revenue of INR33.6b in 2QFY23 (est. INR33.2b), up 11% YoY. EBITDA margin stood at 12.9% (est. 13.2%), led by a lower gross margin of 41.7% in 2QFY23 v/s 42.8% in 2QFY22. EBITDA rose 5% YoY to INR4.34b (est. INR4.38b). Adj. PAT was at INR2.5b (v/s est. INR2.9b), down 13% YoY.
- Revenue in the Indian Branded/International business grew 9%/7% YoY to INR21.6b/INR8.4b, with EBIT at +26%/-46% YoY to INR3.1b/INR597m in 2QFY23, respectively.
- Volumes in India Beverages declined marginally by 1% YoY, while the same in Foods remained flat in 2QFY23. Its strong growth trajectory in Salt continued, with a revenue growth of 27%. The Tata Sampann portfolio grew 37%, led by the strong performance across pulses, poha and spices.
- Revenue from Nouisnco grew 64% to INR1.4b, with broad-based growth across products and geographies. Tata Starbucks rose 57% YoY fueled by normalization in store operations and revival in out-of-home consumption trend. It added 25 new stores and entered six new cities in 2QFY23.
- For 1HFY23, Revenue/EBITDA/Adjusted PAT grew 11%/10%/11%, respectively. CFO/Net Cash stood at INR3b/INR20b in 1HFY23, respectively.

### Highlights from the management commentary

- Tea – The management expects tea prices to continue its downtrend. The company is witnessing stress in semi-urban and rural regions while urban region is performing better.
- International business – TATACONS will be taking structural cost-saving actions to mitigate input cost inflation, adverse currency movement and lag in pricing.
- Tata Sampann portfolio posted strong double-digit growth (37%) in 2QFY23, led by broad-based performance across pulses, poha and spices. The management is expecting this segment to sustain a CAGR of 30% going forward.

Sumant Kumar - Research Analyst (Sumant.Kumar@motilalosal.com)

Research Analyst: Meet Jain (Meet.Jain@motilalosal.com) | Omkar Shintre (Omkar.Shintre@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilalosal.com/Institutional-Equities](http://www.motilalosal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

**Valuation and view**

- TATACONS is on a portfolio expansion spree in its F&B segment, with product launches in new and innovative categories such as ready-to-cook/eat, mini meals, breakfasts, cereals, snacks, ready-to-drink (RTD), and protein-based products. The Food business is likely to be the growth engine for the company, with Tata Sampann leading from the front.
- We expect a sales/EBITDA/PAT CAGR of 11%/18%/30% over FY22-24, respectively. Factoring in an in-line performance in 2QFY23, we maintain our FY23 and FY24 earnings estimates. **We maintain our BUY rating on the stock with an SoTP-based TP of INR880.**

**Consolidated - Quarterly Earnings Model**

(INR b)


Y/E March	FY22				FY23				FY22	FY23E	FY23E	Var (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
<b>Gross Sales</b>	<b>30.1</b>	<b>30.3</b>	<b>32.1</b>	<b>31.8</b>	<b>33.3</b>	<b>33.6</b>	<b>35.6</b>	<b>35.1</b>	<b>124.3</b>	<b>137.7</b>	<b>33.2</b>	<b>1</b>
YoY Change (%)	10.9	9.1	4.5	4.5	10.6	10.9	11.1	10.7	7.1	10.8	9.6	
Total Expenditure	26.1	26.2	27.5	27.3	28.7	29.3	30.6	30.2	107.1	118.7	28.9	
<b>EBITDA</b>	<b>4.0</b>	<b>4.1</b>	<b>4.6</b>	<b>4.4</b>	<b>4.6</b>	<b>4.3</b>	<b>5.0</b>	<b>5.0</b>	<b>17.2</b>	<b>18.9</b>	<b>4.4</b>	<b>-1</b>
Margins (%)	13.3	13.6	14.4	14.0	13.7	12.9	14.2	14.2	13.8	13.8	13.2	
Depreciation	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	2.8	2.9	0.7	
Interest	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.7	0.7	0.2	
Other Income	0.3	0.4	0.3	0.5	0.4	0.3	0.4	0.5	1.4	1.5	0.5	
<b>PBT before EO expense</b>	<b>3.4</b>	<b>3.6</b>	<b>4.0</b>	<b>4.0</b>	<b>4.0</b>	<b>3.7</b>	<b>4.5</b>	<b>4.6</b>	<b>15.1</b>	<b>16.9</b>	<b>3.9</b>	
Extra-Ord expense	0.0	-0.2	-0.1	-0.2	-0.2	1.1	0.0	0.0	-0.5	0.9	0.0	
<b>PBT</b>	<b>3.4</b>	<b>3.5</b>	<b>3.9</b>	<b>3.8</b>	<b>3.8</b>	<b>4.8</b>	<b>4.5</b>	<b>4.6</b>	<b>14.6</b>	<b>17.7</b>	<b>3.9</b>	
Tax	1.0	0.9	1.0	1.0	1.0	1.3	1.2	1.2	3.8	4.7	1.1	
Rate (%)	28.1	23.7	24.9	23.6	25.5	34.2	26.5	26.5	25.0	28.0	27.0	
Minority Interest	0.2	0.2	0.3	0.2	0.2	0.6	0.2	0.2	0.8	1.2	0.2	
Profit/Loss of Asso. Cos.	-0.4	0.2	0.0	-0.5	0.0	0.3	0.0	-0.2	-0.6	0.2	280.7	
<b>Reported PAT</b>	<b>1.9</b>	<b>2.7</b>	<b>2.7</b>	<b>2.2</b>	<b>2.6</b>	<b>3.3</b>	<b>3.1</b>	<b>3.0</b>	<b>9.4</b>	<b>12.0</b>	<b>2.9</b>	
<b>Adj PAT</b>	<b>1.9</b>	<b>2.8</b>	<b>2.7</b>	<b>2.3</b>	<b>2.7</b>	<b>2.4</b>	<b>3.1</b>	<b>3.0</b>	<b>9.7</b>	<b>11.3</b>	<b>2.9</b>	<b>-17</b>
YoY Change (%)	-28.8	3.3	23.4	104.3	45.4	-12.7	14.3	30.5	11.8	16.4	5.1	
Margins (%)	6.3	9.2	8.6	7.3	8.2	7.3	8.8	8.6	7.8	8.2	8.9	

**Key Performance Indicators**

Y/E March	FY22				FY23				FY22	FY23
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
<b>Consolidated</b>										
<b>Revenue Growth (%)</b>										
Standalone	22.5	14.5	3.5	5.3	5.6	7.2	11.9	13.3	10.9	9.5
Overseas Tea Biz	-2.1	-0.9	-3.9	-4.2	15.3	3.4	5.0	5.0	-2.9	7.1
Tata Coffee Ltd (TCL) Consol	-9.3	0.9	17.5	11.0	24.3	30.9	13.9	7.7	4.8	18.5
TCL Standalone	2.2	2.3	39.7	4.4	29.4	37.7	12.0	9.1	10.9	21.0
Coffee Overseas	-14.3	0.2	8.2	14.9	21.8	27.4	15.0	7.0	1.9	17.2
<b>EBITDA Margin (%)</b>										
Standalone	13.9	13.5	13.8	14.8	14.8	15.8	15.6	15.5	14.0	15.4
Overseas Tea Biz	6.9	8.5	11.9	8.0	5.8	3.1	7.9	8.4	8.9	6.4
TCL Consol	16.9	18.6	18.5	16.9	17.6	11.4	14.5	15.0	17.7	14.6
TCL Standalone	9.0	10.1	9.8	10.8	13.7	12.2	11.9	9.4	9.9	11.8
Coffee Overseas	21.0	23.2	23.2	20.2	19.7	11.0	15.9	18.0	21.8	16.1
<b>Cost Break-up</b>										
RM Cost (% of sales)	59.2	57.2	56.3	55.4	57.4	58.3	57.4	56.9	57.3	57.5
Staff Cost (% of sales)	8.8	8.4	8.1	8.4	8.3	8.1	7.7	8.5	8.4	8.2
Adv. and Sales (% of sales)	5.3	7.0	7.6	7.1	6.4	6.4	7.2	6.8	6.8	6.7
Other Cost (% of sales)	13.4	13.7	13.6	15.1	14.2	14.3	13.5	13.6	14.0	13.9
Gross Margins (%)	40.8	42.8	43.7	44.6	42.6	41.7	42.6	43.1	43.0	42.5
EBITDA Margins (%)	13.3	13.6	14.4	14.0	13.7	12.9	14.2	14.2	13.8	13.8
EBIT Margins (%)	11.1	11.3	12.2	11.7	11.6	10.7	12.1	12.1	11.6	11.6


## Key exhibits

**Exhibit 1: Consolidated revenue trend**




Source: Company, MOFSL

**Exhibit 2: Consolidated EBITDA trend**




Source: Company, MOFSL

**Exhibit 3: Consolidated adjusted PAT trend**




Source: Company, MOFSL

**Exhibit 4: Standalone revenue trend**




Source: Company, MOFSL

**Exhibit 5: Standalone EBITDA trend**




Source: Company, MOFSL

**Exhibit 6: Standalone adjusted PAT trend**




Source: Company, MOFSL

**Exhibit 7: Revenue trend in TATACONS's overseas Tea business**




Source: Company, MOFSL

**Exhibit 8: EBITDA trend in TATACONS's overseas Tea business**




Source: Company, MOFSL

**Exhibit 9: Consolidated revenue trend for TCL**




Source: Company, MOFSL

**Exhibit 10: Consolidated EBITDA trend for TCL**




Source: Company, MOFSL

**Exhibit 11: Standalone revenue trend for TCL**




Source: Company, MOFSL

**Exhibit 12: Standalone EBITDA trend for TCL**




Source: Company, MOFSL

**Exhibit 13: Tata Coffee's overseas revenue trend**




Source: Company, MOFSL

**Exhibit 14: Tata Coffee's overseas EBITDA trend**




Source: Company, MOFSL

Exhibit 15: Revenue at a glance (2QFY23)




Source: Company, MOFSL

Exhibit 16: Revenue at a glance (1HFY23)




Source: Company, MOFSL

Exhibit 17: Expanding reach across channels



Source: Company, MOFSL

Exhibit 18: TATACONS' F&B platforms



Source: Company, MOFSL

Exhibit 19: Addition of new growth platform with introduction of Protein-focused products

ALL-NEW

## PLANT PROTEIN

to help women #GoFitEveryday

Added gut-friendly probiotics

18g PROTEIN PER 25g SERVE

The Indian protein supplement market was estimated at **INR 2000Cr** in '21<sup>1</sup>

It is expected to grow at a CAGR of ~18% over 2022-27, reaching **INR 5000Cr** by '27<sup>1</sup>

The plant-based protein supplement market growth is being driven by 3 key factors:

- Growing interest in 'feel-good' fitness beyond physicality
- Active search for more 'natural' alternatives
- Increase in understanding of nutraceuticals

The category is on a structural uptrend enabled by digital

A 2017 survey shows that **73%** of Indians are deficient in protein<sup>2</sup>

**50%+** of the population in the age bracket of 15-49 years is digitally connected with global trends and looking to improve their lifestyle<sup>3</sup>

**~40%+** of the category sells digitally on marketplaces, D2C sites and health stores<sup>1</sup>

<sup>1</sup> Marc Analysis, Feb 2022  
<sup>2</sup> Observer Research Foundation  
<sup>3</sup> Internal and external estimates

Source: Company, MOFSL

**Exhibit 20: Consolidated segmental results**

INR m	2QFY22	1QFY23	2QFY23	%/bp ch YoY	%/bp ch QoQ
<b>Segmental revenue</b>					
<b>Branded Business</b>					
India - Beverages	12,659	13,090	12,380	-2.2%	-5.4%
India - Foods	7,122	8,362	9,220	29.4%	10.3%
International - Beverages	7,813	8,366	8,389	7.4%	0.3%
<b>Total Branded Business</b>	<b>27,594</b>	<b>29,818</b>	<b>29,988</b>	<b>8.7%</b>	<b>0.6%</b>
Non-Branded Business	2,799	3,517	3,718	32.8%	5.7%
<b>Total Segment Revenue</b>	<b>30,393</b>	<b>33,335</b>	<b>33,706</b>	<b>10.9%</b>	<b>1.1%</b>
Others	63	74	137		
Inter segment sales	-124	-141	-213		
<b>Revenue from Operations</b>	<b>30,331</b>	<b>33,268</b>	<b>33,631</b>	<b>10.9%</b>	<b>1.1%</b>
<b>Segment Results</b>					
<b>Branded Business</b>					
India - Business	2,445	2,732	3,077	25.8%	12.6%
International - Beverages	1,097	1,045	597	-45.6%	-42.8%
<b>Total Branded Business</b>	<b>3,542</b>	<b>3,776</b>	<b>3,674</b>	<b>3.7%</b>	<b>-2.7%</b>
<b>Non-Branded Business</b>	<b>215</b>	<b>394</b>	<b>300</b>	<b>39.2%</b>	<b>-23.9%</b>
<b>Total Segment Results</b>	<b>3,758</b>	<b>4,170</b>	<b>3,974</b>	<b>5.8%</b>	<b>-4.7%</b>
<b>EBIT margins</b>					
India - Business	12.4%	12.7%	14.2%	188	151
International - Beverages	14.0%	12.5%	7.1%	(692)	(537)
Total Branded Business	12.8%	12.7%	12.3%	(59)	(41)
Non-Branded Business	7.7%	11.2%	8.1%	37	(314)

Note: India – Business includes India – Beverages and India – Foods

Source: Company, MOFSL

**Highlights from the management commentary****India Packaged Beverages**

- India Packaged Beverages business witnessed revenue decline of 7% YoY in 2QFY23 due to pricing corrections and overall softness in the category. Further, the segment saw volume decline of 1% during 2QFY23. TATACONS continued to record market share gains in terms of volume in its branded tea segment.
- **Tea:** The segment continued to record volume market share gains (+46bp YoY), while value market share (-20bp YoY) declined marginally on price cuts.
- Softness in Tea demand is coming from rural and semi-urban regions of India with stress originating from select geographies such as the Hindi belt.
- TATACONS continued with its premiumization drive, as premium tea portfolio witnessed faster growth than the base portfolio
- The company has taken price cuts in tea portfolio in line with tea prices. The management expects the tea prices to continue its downtrend.
- Tata Tea Kanan Devan recorded its highest-ever volumes in Kerala aided by on-ground activations during Onam.
- **Coffee** continued its strong performance with 39% revenue growth in 2QFY23. During the quarter, TATACONS launched a new season range for its premium coffee range 'Sonnets – by Tata Coffee'

**India Foods business**

- The India Foods business registered 29% YoY revenue growth in 2QFY23 despite an elevated base of 23% growth in 2QFY22 with market share gains of 128bp YoY in salt. The segment recorded flattish volume growth v/s 2QFY22. On three-year CAGR basis, the segment recorded revenue growth of 14% p.a.

- **Tata Sampann** portfolio clocked strong double-digit growth during the quarter, led by broad-based performance across pulses, poha and spices.
- It launched a new campaign with Bollywood actor 'Manoj Bajpayee' to build awareness about the goodness of unpolished pulses and the promise of Tata Sampann.
- Tata Sampann spices launched a customized mix for Andhra Pradesh and Telangana to better serve the South Indian market. The spices range expanded its portfolio in India into high-value spices with the launch of Asafoetida (Hing).
- Tata Sampann Dry Fruits is scaling up well with strong growth and share gains across e-commerce platforms
- **Tata Sampann is expected to post 30% CAGR going forward aided by expansion into new products and new geographies.**
- Accordingly, TATACONS re-launched its **Ready-To-Eat (RTE)** business (formerly Tata Q) with a revamped and expanded portfolio under the new brand name of Tata Sampann Yumside in India and Tata Rassa in international market. The products are launched under different brand names due to copyright issues in India. This includes reformulation of existing products to enhance overall consumer experience and expansion into the ethnic RTE category. The brand will also be launching ethnic innovations in the Ready to Cook (RTC) category.
- **Tata Soulfull** delivered strong growth during the quarter. Tata Soulfull Masala Oats+, a 'better for you' offering with oats and millets, saw good consumer response across key channels. New enhanced Tata Soulfull millets muesli with 25% millets was launched to further strengthen the health proposition and provide a better crunchier taste experience to consumers.

#### **TATACONS's Protein Platform – Launch of Tata GoFit**

- TATACONS made another addition to its protein platform with the launch of Tata GoFit – a plant protein powder and a health supplement range for women
- The product has been specially developed for women and has an innovative and differentiated formulation with digestion-friendly enzymes and gut-friendly probiotics.

#### **India Salt**

- The salt portfolio continued its momentum and recorded double-digit growth during 2QFY23 despite a high base in 2QFY22. The salt portfolio continued to record market share gains (+128bp YoY).
- Tata Salt Immuno was successfully launched in newer markets in the western part of the country. The brand was launched with new & improved packaging to better showcase the Zinc proposition
- The company has launched 'Shuddh - from Tata salt' in previous quarter. While management believes the product to be better than other competitor product in south, it feels that product sizing and packaging needs to be altered.

#### **Tata Coffee (including Vietnam ex EOC)**

- Revenue for the quarter grew 41% YoY (with constant currency growth of 39% YoY) led by strong growth across both the extractions and coffee plantations. Volumes declined by 1% YoY in 2QFY23.



- Inflationary challenges continued during the quarter, but they were mitigated through cost management efforts.
- **Extractions:** Overall extraction business grew 26% YoY in 2QFY23 driven by both the domestic and the Vietnam business
- Vietnam plant continued to operate at peak capacity utilization with sales witnessing 43% YoY growth driven by higher sales of premium products and superior realization.
- **Plantations:** In 2QFY23 plantations revenue grew 73% YoY driven by higher realization and sales of Robusta coffee and pepper.

#### NourishCo

- Nourish Co sustained strong growth momentum with revenue growth of 64% in 2QFY23 on back of growth across products and geographies.
- Himalayan recorded excellent growth and continued to remain EBIT positive during the quarter. Himalayan honey and preserves saw good consumer response.
- Himalayan clocked revenue growth of 72% YoY and continued to remain EBIT positive during the quarter. The growth was led by all products and geographies.
- The business is seeing inflation in input cost and freight, but it was mitigated through cost-saving initiatives and operating leverage during the quarter.
- Tata Copper Water witnessed revenue growth of 91% YoY

#### JV: Starbucks

- Tata Starbucks saw strong revenue growth of 57% YoY during the quarter aided by normalized store operations and a revival in out-of-home consumption.
- It has opened 25 new stores during Q2FY23, the highest ever in a quarter in its history and entered five new cities. This brought the total number of stores to 300 across 36 cities.

#### US business

- **Coffee:** Revenue for the quarter grew 16% YoY (constant currency growth) driven by Eight O' Clock (EOC) gaining share (~4.4% of coffee bags market share).
- EOC coffee in the USA recorded share gains, with EOC K Cups growing 2X the category during the quarter, led by 48 SKU counts.
- The newly launched Tetley Sweet Tea Cold Brew strengthened the presence in the specialty tea segment in the USA. Tetley Irish Breakfast tea continued to do well on back of distribution gains and ongoing promotion activity.
- The business profitability has been impacted by an increase in coffee and freight costs and delayed implementation of pack/price initiatives.
- **Tea:** Revenue for the quarter grew 9% YoY (constant currency) in 2QFY23 led by Tetley and Teapigs outperforming their respective categories.
- Teapigs is now the fastest-growing tea brand in the US. Further, Tetley witnessed share gains in the latest period led by performance in mainstream Black with distribution gains and increased activity.

**Canada business**

- Revenue grew 16% YoY (constant currency) with market share of 27.3% in 2QFY23. Revenue growth in Specialty tea category was 11% YoY. The tea category growth is being led by pricing as inflation impacts volumes.
- New distribution for Tata tea is helping the brand grow rapidly, albeit off a small base.

**UK business**

- Revenue for the quarter declined 7% YoY (constant currency) on back of category softness driven by significant inflation.
- Teapigs declined 16% YoY due to an elevated base (2QFY22 growth of 17%) and led by hot weather and moderation in OOH consumption.
- TCPL became the third largest branded tea company by market share in UK, displacing 'Twinings'.
- TATACONS has already taken a 7% price hike which was inadequate and therefore has announced a double digit price hike again. The impact of price hike will be seen by 4QFY23.
- Inflation and GBP depreciation impacted profitability adversely in 2QFY23. These will be addressed through pricing actions and structural cost-saving measures.

**Outlook**

- TATACONS "growth businesses" have sustained their strong growth trajectory. Also, out of home businesses i.e. both NourishCo & Starbucks have delivered strong quarter and management expects continued momentum going forward.
- In the international business, the company will be taking structural cost-saving actions to improve margins.
- Given the inflationary environment and investments required for some of the new businesses, we will continue to manage margins at the company level while remaining focused on maintaining growth momentum.

**Other highlights**

- TATACONS increased its direct reach to 1.4m outlets and witnessed 20% growth in the number of its super stockists.
- Despite high growth in distribution channel, as per management there is significant room to grow at high pace going forward driving overall volume growth for the company.
- TATACONS continued to see strong growth in alternate channels, with Modern Trade channel witnessing growth of 18% YoY. The Ecommerce channel grew 40% contributing to 9.2% of India business sales.
- Alternate channels continued to support the innovation agenda with 11% of Ecommerce revenue is coming from New Product Development (NDP) sales, during the quarter.
- TATACONS is accelerating the pace on innovation with number of product launch doubling in 2QFY23 as compared to 1QFY23. Management expects such newly launched products to contribute to 3.5% of total sales in FY23 and targets to reach 5% going forward.


**Valuation and view**

- The management's holistic strategy aims at: i) strengthening and accelerating its core business, ii) exploring new opportunities, iii) unlocking synergies, iv) digitization of the supply chain, v) expansion of its product portfolio and innovation, vi) enhancing its focus on premiumization and health & wellness products, vii) embedding sustainability, and viii) expanding its sales and distribution infrastructure, supply chain, and capability building towards being a multi-category FMCG player.
- TATACONS is on a portfolio expansion spree in its F&B segment, with product launches in new and innovative categories such as ready-to-cook/eat, mini meals, breakfasts, cereals, snacks, ready-to-drink (RTD), and protein-based products. The Food business is likely to be the growth engine for the company, with Tata Sampann leading from the front.
- We expect a sales/EBITDA/PAT CAGR of 11%/18%/30% over FY22-24, respectively. Factoring in an in-line performance in 2QFY23, we maintain our FY23 and FY24 earnings estimates. **We maintain our BUY rating on the stock with an SoTP-based TP of INR880.**


**Exhibit 21: Valuation methodology**

EV/EBITDA	FY24 EBITDA	Multiple (x)	EV
India Tea (TATACONS standalone)	9,296	41	3,82,063
Coffee India (excluding Starbucks)	1,162	11	12,784
Coffee overseas	4,062	14	57,274
Consumer (Salt and others)	7,067	41	2,91,172
Overseas Tea (Tetley UK)	2,390	13	31,073
<b>DCF</b>			
Starbucks JV			35,349
<b>Enterprise value</b>			<b>8,09,714</b>
Less: Net debt			(28,809)
<b>Market value (INR m)</b>			<b>8,38,523</b>
No. of shares (m)			953
<b>Target price (INR)</b>			<b>880</b>

Source: MOFSL

**Exhibit 22: One-year forward P/B (x)**

Source: MOFSL

**Exhibit 23: One-year forward P/E (x)**

Source: MOFSL

**Exhibit 24: Revisions in our estimates**

Earnings Change (INR m)	Old		New		Change (%)	
	FY23E	FY24E	FY23E	FY24E	FY23E	FY24E
Revenue	1,37,210	1,51,205	1,37,683	1,52,009	0	1
EBITDA	19,263	23,733	18,936	23,978	-2	1
Adj. PAT	11,854	16,395	11,345	16,565	-4	1

Source: MOFSL

## Financials and valuations

Consolidated Income Statement								(INR b)	
Y/E March	2016	2017	2018	2019	2020	2021	2022	2023E	2024E
<b>Net Sales</b>	<b>66.4</b>	<b>67.8</b>	<b>68.2</b>	<b>72.5</b>	<b>96.4</b>	<b>116.0</b>	<b>124.3</b>	<b>137.7</b>	<b>152.0</b>
Change (%)	-17.0	2.2	0.5	6.4	32.9	20.4	7.1	10.8	10.4
<b>Gross Profit</b>	<b>30.1</b>	<b>32.2</b>	<b>31.2</b>	<b>32.4</b>	<b>42.3</b>	<b>47.0</b>	<b>53.4</b>	<b>58.5</b>	<b>66.0</b>
Margin (%)	45.4	47.5	45.7	44.7	43.9	40.5	43.0	42.5	43.4
Other operating exp.	23.6	24.3	22.8	24.6	29.3	31.6	36.2	39.6	42.1
<b>EBITDA</b>	<b>6.5</b>	<b>7.9</b>	<b>8.4</b>	<b>7.9</b>	<b>12.9</b>	<b>15.4</b>	<b>17.2</b>	<b>18.9</b>	<b>24.0</b>
Margin (%)	9.9	11.7	12.3	10.8	13.4	13.3	13.8	13.8	15.8
Depreciation	1.2	1.3	1.2	1.2	2.4	2.5	2.8	2.9	3.0
Net Interest	1.2	0.9	0.4	0.5	0.8	0.7	0.7	0.7	0.6
Other income	0.8	0.8	0.9	1.6	1.1	1.2	1.4	1.5	1.7
<b>PBT before EO</b>	<b>5.0</b>	<b>6.6</b>	<b>7.7</b>	<b>7.7</b>	<b>10.8</b>	<b>13.4</b>	<b>15.1</b>	<b>16.9</b>	<b>22.1</b>
EO income/(exp.)	-3.3	0.1	-0.2	-0.3	-2.7	-0.3	-0.5	0.9	0.0
PBT after EO	1.7	6.6	7.5	7.3	8.1	13.1	14.6	17.7	22.1
Tax	2.0	2.0	1.9	2.6	2.7	3.2	3.8	4.7	6.0
Rate (%)	117.8	30.0	24.7	35.5	33.9	24.2	25.9	26.6	27.0
Minority and Associates	-0.2	0.7	0.7	0.7	0.8	1.4	1.4	1.0	-0.5
<b>Reported PAT</b>	<b>-0.1</b>	<b>3.9</b>	<b>5.0</b>	<b>4.1</b>	<b>4.6</b>	<b>8.6</b>	<b>9.4</b>	<b>12.0</b>	<b>16.6</b>
<b>Adjusted PAT</b>	<b>3.3</b>	<b>3.8</b>	<b>5.2</b>	<b>4.4</b>	<b>7.2</b>	<b>8.7</b>	<b>9.7</b>	<b>11.3</b>	<b>16.6</b>
Change (%)	-13.3	17.3	34.5	-14.6	63.5	20.8	11.8	16.4	46.0

Balance Sheet								(INR b)	
Y/E March	2016	2017	2018	2019	2020	2021	2022	2023E	2024E
Share Capital	0.6	0.6	0.6	0.6	0.9	0.9	0.9	0.9	1.0
Reserves	61.8	62.0	69.7	72.7	137.2	144.4	150.5	162.6	179.7
<b>Net Worth</b>	<b>62.5</b>	<b>62.7</b>	<b>70.3</b>	<b>73.3</b>	<b>138.1</b>	<b>145.3</b>	<b>151.4</b>	<b>163.5</b>	<b>180.7</b>
Minority Interest	8.6	9.2	10.1	10.3	10.9	10.9	11.5	7.1	0.0
Loans	13.5	7.9	10.7	11.3	11.8	7.2	10.1	10.1	8.1
<b>Capital Employed</b>	<b>84.6</b>	<b>79.7</b>	<b>91.1</b>	<b>94.9</b>	<b>160.9</b>	<b>163.5</b>	<b>173.0</b>	<b>180.7</b>	<b>188.8</b>
Gross Block	24.0	23.7	25.4	27.7	59.1	61.8	66.7	69.2	72.2
Less: Accum. Deprn.	14.5	13.7	15.2	16.4	18.8	21.4	24.2	27.1	30.1
<b>Net Fixed Assets</b>	<b>9.5</b>	<b>10.1</b>	<b>10.2</b>	<b>11.3</b>	<b>40.3</b>	<b>40.4</b>	<b>42.5</b>	<b>42.1</b>	<b>42.1</b>
Capital WIP	0.4	0.6	1.4	4.2	1.0	1.1	4.6	4.6	4.6
Goodwill & Intangibles	37.1	35.0	37.2	37.9	73.3	76.0	77.5	77.5	77.5
Investments	11.9	13.5	6.4	6.0	4.9	4.8	6.0	6.2	6.7
<b>Curr. Assets</b>	<b>40.0</b>	<b>36.3</b>	<b>49.3</b>	<b>49.4</b>	<b>65.3</b>	<b>79.9</b>	<b>80.1</b>	<b>89.5</b>	<b>99.3</b>
Inventories	16.3	14.5	14.5	16.1	17.1	22.5	22.7	30.2	30.0
Account Receivables	5.9	5.9	6.5	6.8	9.2	7.6	8.4	11.3	11.7
Cash and Bank Balance	6.7	7.4	18.1	16.2	24.6	34.0	28.0	26.9	36.6
Others	11.1	8.4	10.3	10.3	14.4	15.8	21.1	21.1	21.1
<b>Curr. Liability &amp; Prov.</b>	<b>13.5</b>	<b>14.3</b>	<b>13.5</b>	<b>12.9</b>	<b>20.8</b>	<b>33.2</b>	<b>30.2</b>	<b>31.8</b>	<b>34.0</b>
Account Payables	6.8	7.4	7.1	6.6	9.4	16.3	19.2	20.7	22.9
Other liabilities	2.8	3.4	3.6	4.2	8.6	14.0	8.6	8.6	8.6
Provisions	4.0	3.6	2.9	2.0	2.8	2.9	2.5	2.5	2.5
<b>Net Curr. Assets</b>	<b>26.5</b>	<b>22.0</b>	<b>35.8</b>	<b>36.5</b>	<b>44.5</b>	<b>46.6</b>	<b>49.8</b>	<b>57.7</b>	<b>65.4</b>
Def. tax liability	0.8	1.5	0.0	1.0	3.0	5.5	7.5	7.5	7.5
<b>Appl. of Funds</b>	<b>84.6</b>	<b>79.7</b>	<b>91.1</b>	<b>94.9</b>	<b>160.9</b>	<b>163.5</b>	<b>173.0</b>	<b>180.7</b>	<b>188.8</b>

## Financials and valuations

Cash flow statement								(INR b)	
Y/E March	2016	2017	2018	2019	2020	2021	2022	2023E	2024E
<b>EBITDA</b>	<b>6.5</b>	<b>7.9</b>	<b>8.4</b>	<b>7.9</b>	<b>12.9</b>	<b>15.4</b>	<b>17.2</b>	<b>18.9</b>	<b>24.0</b>
Prov. & FX	-0.1	0.0	0.0	0.0	-0.1	0.0	0.0	0.0	0.0
WC	-2.7	1.5	-1.4	-2.3	-0.6	3.1	2.0	-8.9	1.8
Others	-0.2	0.1	-0.4	-0.8	1.4	1.2	-0.3	0.9	0.0
Direct taxes (net)	-2.3	-2.1	-3.0	-2.6	-2.7	-3.2	-3.8	-4.7	-6.0
<b>CF from Op. Activity</b>	<b>1.2</b>	<b>7.4</b>	<b>3.6</b>	<b>2.1</b>	<b>10.8</b>	<b>16.6</b>	<b>15.2</b>	<b>6.2</b>	<b>19.8</b>
Capex	-1.5	-1.4	-3.6	-2.8	-1.6	-2.1	-2.7	-2.5	-3.0
<b>FCFF</b>	<b>-0.4</b>	<b>6.0</b>	<b>0.0</b>	<b>-0.7</b>	<b>9.2</b>	<b>14.5</b>	<b>12.4</b>	<b>3.7</b>	<b>16.8</b>
Interest/dividend	0.7	0.6	0.5	0.5	0.6	0.7	0.9	1.5	1.7
Investments in subs/assoc.	-0.5	-0.3	-0.1	-0.4	-0.2	-2.2	-7.4	0.0	0.0
Others	4.3	2.5	10.2	3.4	-5.5	-0.5	-4.0	0.0	0.0
<b>CF from Inv. Activity</b>	<b>2.9</b>	<b>1.4</b>	<b>7.0</b>	<b>0.7</b>	<b>-6.7</b>	<b>-4.1</b>	<b>-13.2</b>	<b>-1.0</b>	<b>-1.3</b>
Share capital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Borrowings	-0.8	-4.8	2.2	0.4	0.3	-0.6	-4.9	0.0	-2.0
Finance cost	-0.7	-0.6	-0.3	-0.4	-0.7	-0.7	-0.6	-0.7	-0.6
Dividend	-1.9	-1.9	-2.1	-2.2	-2.2	-2.7	-4.0	-5.6	-6.2
Others	0.5	-0.8	0.4	-2.5	6.9	0.9	1.6	0.0	0.0
<b>CF from Fin. Activity</b>	<b>-2.8</b>	<b>-8.2</b>	<b>0.1</b>	<b>-4.7</b>	<b>4.3</b>	<b>-3.0</b>	<b>-7.9</b>	<b>-6.3</b>	<b>-8.8</b>
<b>(Inc)/Dec in Cash</b>	<b>1.3</b>	<b>0.7</b>	<b>10.7</b>	<b>-1.9</b>	<b>8.4</b>	<b>9.4</b>	<b>-6.0</b>	<b>-1.1</b>	<b>9.7</b>
Opening balance	5.5	6.7	7.4	18.1	16.2	24.6	34.0	28.0	26.9
<b>Closing balance (as per B/S)</b>	<b>6.7</b>	<b>7.4</b>	<b>18.1</b>	<b>16.2</b>	<b>24.6</b>	<b>34.0</b>	<b>28.0</b>	<b>26.9</b>	<b>36.6</b>

### Ratios

Y/E March	2016	2017	2018	2019	2020	2021	2022	2023E	2024E
<b>Basic (INR)</b>									
<b>EPS</b>	<b>3.6</b>	<b>4.2</b>	<b>5.6</b>	<b>4.8</b>	<b>7.8</b>	<b>9.5</b>	<b>10.6</b>	<b>12.2</b>	<b>17.4</b>
Cash EPS	4.8	5.5	6.9	6.1	10.5	12.2	13.6	15.4	20.5
BV/Share	67.8	68.0	76.3	79.6	149.9	157.7	164.3	176.0	189.6
DPS	2.3	2.3	2.4	2.5	2.7	4.1	6.1	6.1	6.5
Payout (%)	NA	36.5	29.9	38.7	54.1	43.6	59.6	46.8	37.4
Dividend yield (%)	0.3	0.3	0.3	0.3	0.4	0.5	0.8	0.8	0.9
<b>Valuation (x)</b>									
P/E	214.4	182.7	135.8	159.0	97.2	80.5	72.0	62.4	43.8
Cash P/E	158.0	137.6	110.9	124.4	72.8	62.3	56.0	49.5	37.1
P/BV	11.2	11.2	10.0	9.6	5.1	4.8	4.6	4.3	4.0
EV/Sales	10.7	10.4	10.2	9.6	7.1	5.8	5.5	5.0	4.4
EV/EBITDA	108.3	88.8	82.8	88.7	53.3	43.7	39.8	36.2	28.1
Dividend Yield (%)	0.3	0.3	0.3	0.3	0.4	0.5	0.8	0.8	0.9
FCF per share	-0.6	9.6	-0.1	-1.1	10.0	15.7	13.5	4.0	17.6
<b>Return Ratios (%)</b>									
RoE	5.6	6.1	7.8	6.1	6.8	6.1	6.6	7.2	9.6
RoCE	7.6	9.0	9.4	8.6	8.5	8.3	9.0	10.1	12.5
RoIC	8.2	10.6	11.7	9.8	11.5	11.1	10.7	11.7	15.0
<b>Working Capital Ratios</b>									
Fixed Asset Turnover (x)	7.0	6.7	6.7	6.4	2.4	2.9	2.9	3.3	3.6
Asset Turnover (x)	0.8	0.9	0.7	0.8	0.6	0.7	0.7	0.8	0.8
Debtor (Days)	33	32	35	34	35	24	25	30	28
Creditor (Days)	37	40	38	33	36	51	56	55	55
Inventory (Days)	90	78	78	81	65	71	67	80	72
<b>Leverage Ratio (x)</b>									
Net Debt/Equity	0.1	0.0	-0.1	-0.1	-0.1	-0.2	-0.1	-0.1	-0.2

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

#### Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however, the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-3980 4263; [www.motilaloswal.com](http://www.motilaloswal.com). Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: [na@motilaloswal.com](mailto:na@motilaloswal.com), Contact No.:022-71881085.

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL: IN-DP-16-2015; NSDL: IN-DP-NSDL-152-2000; Research Analyst: INH000000412. AMFI: ARN.: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products. Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dp\\_grievances@motilaloswal.com](mailto:dp_grievances@motilaloswal.com).